Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC Riviciclib hydrochloride | 920113-03-7 | 99.1% | 438.30 | 50 MG
Supplier: Medchemexpress LLC HY1655950MG
Riviciclib hydrochloride is a potent cyclin-dependent kinase (CDK) inhibitor, inhibiting CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively. It demonstrates antitumor activity on cisplatin-resistant cells.
- Shows no detectable G1 and G2 cells in promyelocytic leukemia, and G1 arrest in synchronized human non-small cell lung carcinoma (H-460) and human normal lung fibroblast (WI-38) cells.
- Reduces cyclin D1, Cdk4, and Rb levels in H-460 cells; Rb phosphorylation decreases at 3 h.
- Active in human cancer cell lines including colon carcinoma, osteosarcomal, cervical carcinoma, and bladder carcinoma.
- Significantly inhibits growth of human colon carcinoma HCT-116 xenograft in models.
- Significantly inhibits growth in human xenograft models with daily or twice daily treatments.
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?